NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform [Yahoo! Finance]
NLS Pharmaceutics Ltd. - Common Shares (NLSP)
Company Research
Source: Yahoo! Finance
Medications activating dual OX1R/OX2R target a broader range of mechanisms involved in neurologic disorders including narcolepsy and other hypersomnolence disorders Additional targets covered by the exclusive License Agreement include cathepsins, sigma receptors and catecholaminergic inhibition, addressing neuroprotection, neuroinflammation and neurotransmission. First patent application was filed at the end of 2022 for orexin receptors agonists for treating or preventing neurological diseases and psychiatric disorders including narcolepsy. With this groundbreaking License Agreement, NLS continues to strengthen its neuroscience pipeline in sleep medicine with a unique and holistic approach to central disorders of hypersomnolence and neurodegenerative disorders franchise. NLS to start immediately focusing on these disease modifying compounds which have the potential to be first as well as best in class. ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Lt
Show less
Read more
Impact Snapshot
Event Time:
NLSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLSP alerts
High impacting NLS Pharmaceutics Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
NLSP
News
- NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing [Yahoo! Finance]Yahoo! Finance
- NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingAccesswire
- NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering Accesswire
- NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
NLSP
Sec Filings
- 4/19/24 - Form 6-K
- 4/15/24 - Form 6-K
- 4/8/24 - Form 6-K
- NLSP's page on the SEC website